Tumor progression-related transmembrane protein aspartate-β- hydroxylase is a target for immunotherapy of hepatocellular carcinoma

Journal of Hepatology

Volumn 56, Issue 5, 2012, Pages 1129-1135

  Shimoda, Masafumi ^a,b   Tomimaru, Yoshito ^a   Charpentier, Kevin P ^a   Safran, Howard ^a   Carlson, Rolf I ^a   Wands, Jack ^a  

^a BROWN UNIVERSITY   (United States)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Aspartate hydroxylase; CD4+ cells; Dendritic cells; Hepatocellular carcinoma; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE BETA HYDROXYLASE; CYTOKINE; INTERLEUKIN 12; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INFILTRATION; CANCER PREVENTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; INOCULATION; LIVER CELL CARCINOMA; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CALCIUM-BINDING PROTEINS; CARCINOMA, HEPATOCELLULAR; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MIXED FUNCTION OXYGENASES; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL;

EID: 84859733767     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.12.016     Document Type: Article

References (49)

1. Shimoda M, Wands JR. Molecular biology of liver carcinogenesis and hepatitis. In: Blumgart J, editor. Blumgart's Surgery of the Liver. Elsevier; 2012 (in press).
2. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global Cancer Facts & Figures 2007. American Cancer Society; 2007.
3. Hertl M, Cosimi AB. Liver transplantation for malignancy. Oncologist 2005;10:269-281. (Pubitemid 40559592)
4. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999;229:790-799 (discussion 799-800).
5. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593-603. (Pubitemid 35174678)
6. Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, et al. CDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem 1992;267:14322-14327.
7. Goldbrunner RH, Haugland HK, Klein CE, Kerkau S, Roosen K, Tonn JC. ECM dependent and integrin mediated tumor cell migration of human glioma and melanoma cell lines under serum-free conditions. Anticancer Res 1996;16:3679-3687. (Pubitemid 27085032)
8. Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, et al. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1996;98:1313-1323. (Pubitemid 26322056)
9. Merzak A, Koochekpour S, Pilkington GJ. Adhesion of human glioma cell lines to fibronectin, laminin, vitronectin and collagen I is modulated by gangliosides in vitro. Cell Adhes Commun 1995;3:27-43.
10. Tucker RP, Kenzelmann D, Trzebiatowska A, Chiquet-Ehrismann R. Teneurins: transmembrane proteins with fundamental roles in development. Int J Biochem Cell Biol 2007;39:292-297. (Pubitemid 44855663)
11. Harada Y, Yonemitsu Y. Dramatic improvement of DC-based immunotherapy against various malignancies. Front Biosci 2012;17:2233-2242.
12. de la Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006;44:971-983.
13. Maeda T, Sepe P, Lahousse S, Tamaki S, Enjoji M, Wands JR, et al. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol 2003;38:615-622. (Pubitemid 36560646)
14. Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010;52:164-173.
15. Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology 2006;44:446-457. (Pubitemid 44214884)
16. Gehring S, Gregory SH, Wintermeyer P, San Martin M, Aloman C, Wands JR. Generation and characterization of an immunogenic dendritic cell population. J Immunol Methods 2008;332:18-30.
17. Moser JM, Sassano ER, Leistritz del C, Eatrides JM, Phogat S, Koff W, et al. Optimization of a dendritic cell-based assay for the in vitro priming of naive human CD4+ T cells. J Immunol Methods 2010;353:8-19.
18. Toldbod HE, Agger R, Bolund L, Hokland M. Potent influence of bovine serum proteins in experimental dendritic cell-based vaccination protocols. Scand J Immunol 2003;58:43-50. (Pubitemid 36819196)
19. den Haan JM, Kraal G, Bevan MJ. Cutting edge: lipopolysaccharide induces IL-10-producing regulatory CD4+ T cells that suppress the CD8+ T cell response. J Immunol 2007;178:5429-5433. (Pubitemid 46674336)
20. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008;322:1097-1100.
21. Patek PQ, Collins JL, Cohn M. Transformed cell lines susceptible or resistant to in vivo surveillance against tumorigenesis. Nature 1978;276:510-511. (Pubitemid 9055811)
22. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-2368. (Pubitemid 29028508)
23. Muranski P, Restifo NP. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009;21:200-208.
24. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, van Kooten C, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994;12:881-922. (Pubitemid 24140434)
25. Chattopadhyay PK, Yu J, Roederer M. A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles. Nat Med 2005;11:1113-1117. (Pubitemid 41486835)
26. Frentsch M, Arbach O, Kirchhoff D, Moewes B, Worm M, Rothe M, et al. Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005;11:1118-1124. (Pubitemid 41486836)
27. Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A, et al. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res 2005;11:6686-6694. (Pubitemid 41339010)
28. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol 2005;174:1709-1716.
29. Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006;43:1284-1294. (Pubitemid 43980107)
30. Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, et al. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients. Clin Cancer Res 2004;10:6946-6955. (Pubitemid 39383045)
31. Yoon H, Lee H, Kim HJ, You KT, Park YN, Kim H. Tudor domain-containing protein 4 as a potential cancer/testis antigen in liver cancer. Tohoku J Exp Med 2011;224:41-46.
32. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med 2007;5:3.
33. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, et al. Tcell responses to HLA-A?0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003;9:5902-5908. (Pubitemid 38018074)
34. Ding FX, Wang F, Lu YM, Li K, Wang KH, He XW, et al. Multiepitope peptide-loaded virus-like particles as a vaccine against hepatitis B virus-related hepatocellular carcinoma. Hepatology 2009;49:1492-1502.
35. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006;12:2689-2697.
36. Motomura Y, Senju S, Nakatsura T, Matsuyoshi H, Hirata S, Monji M, et al. Embryonic stem cell-derived dendritic cells expressing glypican-3, a recently identified oncofetal antigen, induce protective immunity against highly metastatic mouse melanoma, B16-F10. Cancer Res 2006;66: 2414-2422.
37. Kuang M, Peng BG, Lu MD, Liang LJ, Huang JF, He Q, et al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 2004;10: 1574-1579. (Pubitemid 38435545)
38. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005;28:496-504.
39. Longato L, de la Monte S, Kuzushita N, Horimoto M, Rogers AB, Slagle BL, et al. Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver. Hepatology 2009;49: 1935-1943.
40. Ince N, de la Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261-1266. (Pubitemid 30151993)
41. Xian ZH, Zhang SH, Cong WM, Yan HX, Wang K, Wu MC. Expression of aspartyl beta-hydroxylase and its clinicopathological significance in hepatocellular carcinoma. Mod Pathol 2006;19:280-286. (Pubitemid 43117613)
42. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 2003;63:3281-3288. (Pubitemid 36735884)
43. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007;104:8947-8952. (Pubitemid 47175417)
44. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-2127.
45. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010;116:1767-1775.
46. Peggs KS, Quezada SA, Korman AJ, Allison JP. Principles and use of anti- CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006;18:206-213. (Pubitemid 43327304)
47. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, et al. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 2011;53:1206-1216.
48. Yeung YA, Finney AH, Koyrakh IA, Lebowitz MS, Ghanbari HA, Wands JR, et al. Isolation and characterization of human antibodies targeting human aspartyl (asparaginyl) beta-hydroxylase. Hum Antibodies 2007;16:163-176. (Pubitemid 351359905)
49. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008;222:129-144. (Pubitemid 351430378)